SYNC Syncona Ord
Syncona Limited is a fund specializes in investments in hedge, equity and long-term alternative investment funds across multiple asset classes. It manages private equity, debt, fixed income and alternative investments. The fund prefers to invest in healthcare and life sciences sector with focus on Cell therapy, gene therapy, biologics and small molecules. The fund invests in the public equity and fixed income markets across the globe. It targets attractive medium to long term returns by investing in leading long-only and alternative investment funds with proven managers and across multiple asset classes. The firm invests in separately managed account portfolios.…
Industry Peers
Capital MarketsKey Statistics
About Syncona Ord (LON: SYNC)
›
Syncona Ord (LON: SYNC) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Capital Markets industry, part of the Financial Services sector, and reports about 1,226 employees.
The shares were at 125.40 GBp on 19 November 2026, up 25.4% over 52 weeks. Its 52-week range is 86.80 GBp to 131.80 GBp: the price is 4.9% below the high and 44.5% above the low.
At a market capitalisation of 762.69M GBP, it trades at 15.7 times trailing earnings and 7.0 times forward earnings. The median trailing P/E of its 19 largest Capital Markets peers is 15.5, so SYNC is valued in line with them.
Syncona Ord reports return on equity of -0.8% and an operating margin of 70.2%.
It holds more cash than debt, a net cash position of 13.00K GBP. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 2 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 211.00 GBp is 68.3% above the current price. The next earnings report is expected on 17 June 2027.